• CD3-ζ chain;
  • gastric carcinoma;
  • lymphocyte;
  • prognosis


  1. Top of page
  2. Abstract


Impaired or reduced CD3 zeta chain (CD3-ζ) expression in T cells has been identified in various cancers and may be associated with an ineffective immune response. The clinical significance of CD3-ζ chain expression in tumor-infiltrating lymphocytes (TILs) in gastric carcinoma remains unclear.


The authors immunohistochemically investigated CD3-ζ expression in TILs in 185 patients who had undergone curative gastrectomy. CD3-ζ/CD3 epsilon (CD3-ϵ) ratios were calculated. Patients were divided into two groups: a normal CD3-ζ group (n = 121) and a reduced CD3-ζ group (n = 64). Patients with a zeta per epsilon ratio of greater than 66% were placed in the normal CD3-ζ group.


Patients in the normal CD3-ζ group had fewer lymph node metastasis (P < 0.01) and a shallower depth of invasion (P < 0.05) than those in the reduced CD3-ζ group. The 5-year survival rate was 72% in the normal CD3-ζ group, which was significantly better than that in the reduced CD3-ζ group (55%; P < 0.01). When stratified according to clinical stage, the prognostic value was significantly different only in Stage IV patients. Multivariate analysis showed that CD3-ζ expression was an independent prognostic factor (P = 0.03) next to depth of invasion and lymph node involvement.


Reduced CD3-ζ expression in TILs was strongly correlated with progressive disease in gastric carcinomas. CD3-ζ expression in TILs is considered an immunologic, independent prognostic marker in gastric carcinoma patients. CD3-ζ normalization with cytokine treatment may lead to prolonged survival in advanced gastric carcinoma patients. Cancer 2002;94:1437–42. © 2002 American Cancer Society.

DOI 10.1002/cncr.10346

Many researchers have demonstrated a significant correlation between tumor-infiltrating lymphocytes (TILs) and clinical outcome in cancer patients.1–4 These findings suggest that tumor cells are eliminated by the host immune system via tumor antigen specific T cells.5 However, cytotoxic lymphocytes around tumor sites do not always exhibit antitumor activity and most are ineffective against autologous tumor cells. Impaired or reduced CD3 zeta chain (CD3-ζ expression is considered to alter or hamper cytoplasmic signaling in activating T cells.6–8 Experimentally reduced or impaired CD3-ζ expression in peripheral T cells first was identified in tumor-bearing mice9 and was found in TILs in malignant lymphoma,10 renal cell carcinoma,11 and in peripheral blood lymphocytes in cervical,12 colon,13 and stomach carcinomas.14 It therefore is believed that CD3-ζ impairment in various types of cancer patients leads to an ineffectiveness in immune response to autologous tumor. Recent studies have shown that antioxidant compounds9 or adoptive immunotherapy15 could normalize or preserve CD3-ζ expression in lymphocytes. This suggests that cytokine stimulation may recover or normalize impaired or reduced CD3-ζ expression, which may improve the immunologic response to tumor cells. In the current study, we retrospectively investigated lymphocytic CD3-ζ expression immunohistochemically and estimated the clinical implication of CD3-ζ expression in gastric carcinoma.


  1. Top of page
  2. Abstract

A total of 185 patients with gastric carcinoma who had undergone curative gastrectomy for gastric carcinoma at Kagoshima University Hospital from 1985 to 1997 were enrolled in the current study. The mean age of this patient population was 63.3 years (range, 30–87; median, 56.5 years), and the male/female ratio was 2.5 (133:52). No patients had received chemotherapy preoperatively (Table 1). Clinical data and pathologic evaluation were assessed according to the General Rules for the Japanese Gastric Cancer Study and Pathology.16

Table 1. Patient Profile
CharacteristicNo. of patients
  1. U: upper third of the stomach; M: middle third of the stomach, L: lower third of the stomach.

Median Age (yrs)67
Operation method
CD3- ζ expression

Resected specimens were longitudinally sliced into 4-mm-thick sections, fixed in 10% formalin solution and embedded in paraffin. Representative sections including the deepest lesion were prepared and stained with hematoxylin and eosin for pathologic diagnosis.

Monoclonal Antibodies and Immunohistochemistry

The anti-CD3-ζ monoclonal antibody (sc-1239; Santa Cruz Biochemistry, Santa Cruz, CA), recognizing the cytoplasmic epitope of CD3-ζ and anti-CD3-ϵ polyclonal antibody (A0452; DAKO, Denmark) were used for detection of CD3-ζ or CD3-ϵ expression.17 Paraffin embedded specimens, including the most invasive tumors were cut into 4-μm slices and used for immunohistochemical staining. After endogenous peroxidase quenching, antigen was recovered by boiling sections at 120 °C and 3.4 atm for 10 minutes in 1% citrate buffer. Primary antibodies were applied at dilutions of 1:200 for CD3-ζ and 1:400 for CD3-ϵ and reacted overnight at 4 °C. A biotinylated secondary antibody was applied. Complexed streptavidin-biotinylated peroxidase was added at a dilution of 1:200, and antigen expression was visualized with diaminobenzidine.

Evaluation of CD3-ζ and CD3-ϵ expression in TILs

Intratumoral CD3-ζ or CD3-ϵ positive lymphocytes were counted in a total of 10 high-power fields (HPF ×400) in the same areas on consecutive slides and averaged. The CD3-ζ/CD3-ϵ ratio was calculated and evaluated according to Gruiji's classification.6 A total of 100 tumor-infiltrating CD3-ϵ positive cells were observed in randomly selected HPFs (×400), and CD3-ζ positive cells were counted in the same areas on consecutive slides. The CD3-ζ/CD3-ϵ ratio was again calculated. Patients having more than 66% (2 of 3) of CD3-ζ/CD3-ϵ were placed in the CD3-ζ normal group, whereas patients with less than 66% of CD3-ζ/CD3-ϵ were placed in the CD3-ζ reduced group.

Statistical Analysis

The analysis of significant differences in categoric variables was performed using the chi-square test. Postoperative survival curves were calculated by the Kaplan–Meier method and analyzed with the generalized Wilcoxson test. Clinical factors were evaluated as independent prognostic factors by multivariate analysis using the Cox proportional hazard model. All P values are based on two-sided testing, and a significant difference was defined as less than 0.05.


  1. Top of page
  2. Abstract

Distribution of CD3 Zeta Positive Lymphocytes in Cancerous or Normal Gastric Tissues

CD3-ϵ positive and CD3-ζ positive cells infiltrating the tumor nest were visualized by immunohistochemical staining (Figs. 1 and 2). The population density of CD3-ζ and CD3–ϵ were evaluated in the same area on consecutive slides. The expression of CD3-ϵ and CD3-ζ in TILs was easily evaluated in the lymph follicle near the tumor (Figs.1a,b). In this example, the CD3-ζ CD3-ϵ was 0.88, indicating normal CD3-ζ expression. Alternatively, in Figure 2, the CD3-ζ CD3-ϵ was calculated to be 0.40, and the patient was placed in the CD3-ζ reduced or impaired group.

thumbnail image

Figure 1. CD3-ζ positive lymphocytic infiltration in peritumoral area. The CD3-ζ CD3—ϵ was 0.88, indicating normal CD3-ζ expression.

Download figure to PowerPoint

thumbnail image

Figure 2. CD3-ϵ positive lymphocytic infiltration in peritumoral area. CD3-ζ CD3-ϵ was 0.40, indicating reduced CD3-ζ expression.

Download figure to PowerPoint

The CD3-ζ/CD3-ϵ ratio in cancerous stroma varied from 0 to 1.0 (average, 0.86) in this population. According to Gruiji's classification, the 185 patients examined were divided into 121 (63%) patients with normal CD3-ζ expression and 64 (37%) with CD3-ζ reduced or impaired expression (Table 1).

Correlation between Zeta Chain Expression and Clinical Factors

Thirty-six patients (73%) with reduced CD3-ζ expression were positive for lymph node involvement, which was significantly higher than the 47 patients (38%) with CD3-ζ normal expression (P < 0.05). Patients with reduced CD3-ζ expression also showed deeper tumor invasion than patients with CD3-ζ normal expression (P < 0.01). Accordingly, patients with normal CD3-ζ expression were in significantly earlier clinical stages of disease than those with reduced CD3-ζ expression (P < 0.05). Lymphatic invasion, histologic pattern and tumor location did not correlate with CD3-ζ expression (Table 2).

Table 2. Clinicopathologic Features of Patients with or without CD3-ζ Chain Expression
FeatureaCD3-ζ normal (n = 121)CD3-ζ reduced (n = 64)P value
  • U: upper third of the stomach; M: middle third of the stomach, L: lower third of the stomach; NS: not significant.

  • a

    Clinicopathologic data were described according to the General Rules for the Japanese Gastric Cancer Study and Pathology.

Depth of invasion
 Well differentiated7435NS
Lymph node involvement
Lymphatic invasion
Tumor location
Clinical stage

Relation between CD3 Zeta Expression and Surgical Outcome

The 5-year survival rate of this patient population was significantly better in patients with normal CD3-ζ expression than in those with reduced CD3-ζ expression (P < 0.01; Fig. 3). When stratified according to clinical stage, Stage IV patients with reduced CD3-ζ expression showed significantly poorer prognoses than patients with normal CD3-ζ expression (P < 0.05; Fig. 4). Univariate analysis showed age, depth of invasion, tumor size, lymph node metastasis, and CD3-ζ expression all were related to prognosis. According to multivariate analysis by gender, age, histology, tumor dimension, depth of invasion, lymph node involvement, and CD3-ζ expression, lymph node involvement (hazard ratio [HR], 1.9; P < 0.001), tumor depth (HR, 1.6; P = 0.004), tumor size (HR, 1.6; P < 0.01), and CD3-ζ expression (HR, 1.42; P = 0.03) were all found to be independent prognostic factors (Table 3).

thumbnail image

Figure 3. Survival curves of gastric cancer patients according to CD3-ζ of tumor infiltrating lymphocytes. There was significant difference between two CD3-ζ groups (P < 0.01).

Download figure to PowerPoint

thumbnail image

Figure 4. Survival curves of gastric carcinoma patients with respective clinical stages according to CD3-ζ of tumor-infiltrating lymphocytes. Only in Stage IV patients, there was significant difference between two CD3-ζ groups (P < 0.05).

Download figure to PowerPoint

Table 3. Univariate and Multivariate Analysis of Clinicopathologic Factors
FactorUnivariate analysis (P value)Multivariate analysis
P valueHazard ratio
Lymph node involvement<0.001<0.0011.7
Depth of invasion<0.0010.0031.6
Tumor dimension0.0090.011.6
CD3 zeta expression0.0020.031.7


  1. Top of page
  2. Abstract

The concept that T cells recognize tumor specific antigen and lyse autologous tumor is broadly accepted by clinical researchers.5, 17–19 Although immunotherapy using tumor antigen specific cytotoxic T lymphocytes has been clinically effective against refractory cancers such as malignant melanoma,20 it was not significantly effective in gastrointestinal carcinoma patients. It is reported that cancer cells directly or indirectly affect CD3-ζ expression in T cells and may interfere in their normal response to autologous tumor.14, 21 Specifically, macrophages induced by cancer cells were considered to decrease or alter the function of CD3-ζ in peripheral or TILs.22, 23 CD3-ζ abnormalities were found in both intratumoral lymphocytes and peripheral blood lymphocytes in patients with various types of malignancies. In the current study, we found that 37% of gastric carcinoma patients demonstrated a reduced CD3-ζ expression, which is similar to levels reported in other types of cancers.6, 17

Our retrospective analysis showed that reduced CD3-ζ expression negatively correlated with lymph node involvement, depth of invasion, and clinical stage of disease, which is in accordance with other studies.17 These findings suggest that the reduced response of T cells to tumor growth provided a favorable environment for tumor extension. CD3-ζ expression was correlated with patient survival in gastric carcinoma, which also agrees with reports on other types of tumors.17, 24

Only observed in patients with Stage IV disease, 5-year survival rates were significantly decreased in patients with reduced CD3-ζ expression than in those with normal CD3-ζ expression. Furthermore, CD3-ζ was found to be an independent prognostic factors in this patient population, which indicates that the presence or absence of CD3-ζ may influence surgical outcome directly. Accordingly, CD3-ζ expression in TILs may be an appropriate prognostic marker in gastric carcinomas. CD3-ζ expression levels obtained from biopsy specimens may provide information on preoperative immunologic status or may suggest the use of immunotherapy in gastric carcinoma patients. Once patients with reduced CD3-ζ expression are identified, treatment with CD3-ζ stimulatory cytokines could be performed in an attempt to normalize CD3-ζ expression in T cells, restoring their antitumor effect.15, 25, 26 Retrieval of CD3-ζ function using immunoactivating cytokines may be effective in Stage IV patients with reduced CD3-ζ expression.


  1. Top of page
  2. Abstract
  • 1
    Okamura T, Kodama Y, Komegawa T, Sano C, Kumashiro R, Inokuchi K. Gastric carcinoma with lymphoid stroma: Correlation to reactive hyperplasia in regional lymph nodes and prognosis. Jpn J Surg. 1983;13: 177183.
  • 2
    Menard S, Tomasic G, Casalini P, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res. 1997;3: 817819.
  • 3
    Songun I, van de Velde CJ, Hermans J, et al. Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). Br J Cancer. 1996;74: 17831788
  • 4
    Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology. 1986;10: 437459.
  • 5
    Rosenberg AS. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Nat Cancer Inst. 1996;88: 16351644.
  • 6
    de Gruijl TD, Bontkes HJ, Peccatori F, et al. Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. Br J Cancer. 1999;79: 11271132.
  • 7
    Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998;58: 53445347.
  • 8
    Ashwell JD, Klausner RD. Genetic and mutational analysis of the T-cell antigen receptor. Ann Rev Immunol. 1990;8: 139168.
  • 9
    Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochosa AC. Alternations in signal transduction molecules in T lymphocytes from tumor bearing mice. Science. 1992;258: 17951798.
  • 10
    Agrawal S, Marquet J, Delfau-Larue MH, et al. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs . J Clin Invest. 1998;102: 17151723.
  • 11
    Tartour E, Latour S, Mathiot C, et al. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL. derived from renal-cell carcinoma: relationship with TIL phenotype and function . Int J Cancer. 1995;63: 205212.
  • 12
    Kono K, Ressing ME, Brandt RM, et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer . Clin Cancer Res. 1996;2: 18251828.
  • 13
    Mulder WM, Bloemena E, Stukart MJ, et al. T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut. 1997;40: 113119.
  • 14
    Kim CW, Choi SH, Chung EJ, et al. Alternation of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology. 1999;67: 123128.
  • 15
    Kono K, Ichihara F, Iizuka H, Sekikawa T, Matsumoto Y. Expression of signal transducing T-cell zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer. Int J Cancer. 1998;78: 301305.
  • 16
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 2nd English ed-. Gastric Cancer. 1998;1: 1024.
  • 17
    Torsten ER, Roger D, Wanger EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998;58: 53445347.
  • 18
    Kawakami Y, Robbins PF, Wang X, et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998;161: 69856992.
  • 19
    Kono K, Rongcun Y, Charo J, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer. 1998;78: 202208.
  • 20
    Kawakami Y, Dang N, Wang X, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother. 2000;23: 1727.
  • 21
    Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transduction zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993;53: 56105612.
  • 22
    Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 1996; 93: 1311913124.
  • 23
    Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996;26: 13081313
  • 24
    Zea AH, Brendan CD, Longo DL, et al. Alternation in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1995;1: 13271335.
  • 25
    Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest. 1998;101: 25792588.
  • 26
    Whiteside TL. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Adv Exp Med Biol. 1998;451: 167171.